ISSN 1301 - 0883 / E-ISSN 1309 - 3886
 
 








  Survivin Expression May Affect The Neoadjuvant Chemotherapy Response in Breast Cancer Patients [Eastern J Med]
Eastern J Med. 2017; 22(4): 147-154 | DOI: 10.5505/ejm.2017.92486  

Survivin Expression May Affect The Neoadjuvant Chemotherapy Response in Breast Cancer Patients

Sinan Demircioğlu1, Mehmet Artaç2, Levent Korkmaz2, Şeyda Gündüz3, Mustafa Karaağaç2, Hasan Esen4, Gülgün Erdoğan5, Zehra Er2, Elif Peştereli5, Lema Tavlı4, Hakan Bozcuk3
1Necmettin Erbakan University Meram Medical Faculty Department of Internal Medicine, Konya, Turkey
2Necmettin Erbakan University Meram Medical Faculty Department Of Medical Oncology, Konya, Turkey
3Akdeniz University Medical Faculty Department Of Medical Oncology, Antalya, Turkey
4Necmettin Erbakan University Meram Medical Faculty Department Of Pathology, Konya, Turkey
5Akdeniz University, Medical Faculty Department Of Pathology, Antalya, Turkey

INTRODUCTION: To investigate whether there is a predictive effect of NF-kappaB, survivin, and Ki-67 expressions on pathological response and disease relapse in breast cancer (BC) patients
METHODS: Ki-67, survivin and NF-kappaB expressions were analyzed in the pathology specimens of breast biopsy before and after neoadjuvant chemotherapy (NeoCT) in BC patients (n=52). Event-free survival (EFS) (defined as recurrence or metastasis free) analyze was performed.
RESULTS: The median overall survival was 43.5 months and the median EFS was 51 months (95% CI: 33.3-68.9) in all patients. The expression percentages of NF-kappaB, survivin, and Ki-67 significantly decreased after NeoCT (p<0.001). Survivin expression level before NeoCT was significantly higher in patients who did not respond to NeoCT than both partial-responders and complete-responders (p=0.038, p=0.010, respectively). Type of NeoCT was the only independent factor on pathological response status (p=0.007). Addition of taxanes to NeoCT improved pathological complete response rates about six times. However, no predictor was found to be a prognostic factor for EFS in multivariate analyze.
DISCUSSION AND CONCLUSION: Higher survivin expression level before NeoCT may be associated with poor pathological response to NeoCT. These findings must be tested with prospective clinical trials.

Keywords: breast cancer, Ki-67, neoadjuvant chemotherapy, NF-kappaB, pathological response, survivin,


Sinan Demircioğlu, Mehmet Artaç, Levent Korkmaz, Şeyda Gündüz, Mustafa Karaağaç, Hasan Esen, Gülgün Erdoğan, Zehra Er, Elif Peştereli, Lema Tavlı, Hakan Bozcuk. Survivin Expression May Affect The Neoadjuvant Chemotherapy Response in Breast Cancer Patients. Eastern J Med. 2017; 22(4): 147-154

Corresponding Author: Sinan Demircioğlu, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
Copyright © 2020 Eastern Journal of Medicine. All Rights Reserved.
Home        |        Contact
LookUs & OnlineMakale